INCY
stock Healthcare BiotechnologyOverall Healthy · 80%
- Fundamentals Strong
- Trajectory Climbing
- Leadership Churning
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Bullish 5 of 5 trend signals bullishRSI 54 — momentum is balanced between buyers and sellers.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 3
- Open
- $97.98
- +6.22%
- Close
- $97.98
- +6.22%
- Current
- $97.98
- Prev close
- $92.24
- Today
- 2.19M
- 3-mo avg
- 1.47M
Earningscalendar synced from Yahoo 57d ago
- Most recent
- Apr 2884 days ago
- Next expected
- Jul 28in 7 days
Recent earnings dates
- Apr 28 84 days ago
- Feb 10 161 days ago
- Oct 28, 2025 266 days ago
- Jul 29, 2025 357 days ago
Past earnings dates come from INCY’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 51d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), INCY’s fundamentals read as strong overall.
At 13.8x, the price is a reasonable multiple of the company's annual profit.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
This company pays no dividend, common for firms reinvesting their profits back into growth.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 25.0% margin is strong; the company keeps a healthy slice of every revenue dollar.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 24.9% return on equity is strong; the company compounds owners' capital well.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 18.5% return on assets is strong; the company squeezes good profit from its assets.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 0.35, the company carries less in liabilities than in equity, a conservative balance sheet.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 3.32, short-term assets comfortably cover short-term bills.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 21.2% from the prior year: strong top-line expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income grew 3845.0% from the prior year: strong profit expansion.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 51d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $3.0B | $3.4B | $3.7B | $4.2B | $5.1B |
| Net income | $948.6M | $340.7M | $597.6M | $32.6M | $1.3B |
| Diluted EPS | $4.27 | $1.52 | $2.65 | $0.15 | $6.41 |
| Dividend / share | — | — | — | — | — |
| Total assets | $4.9B | $5.8B | $6.8B | $5.4B | $7.0B |
| Total liabilities | $1.2B | $1.5B | $1.6B | $2.0B | $1.8B |
| Shareholder equity | $3.8B | $4.4B | $5.2B | $3.4B | $5.2B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $1.1B | $1.2B | $1.1B | $1.2B | $1.4B | $1.5B | $1.3B |
| Net income | $169.5M | $169.5M | -$476.0M | $158.2M | $158.2M | $158.2M | $812.0M | $303.3M |
| Diluted EPS | $-2.04 | $0.54 | $0.90 | $0.80 | $2.04 | $2.11 | $1.46 | $1.47 |
| Dividend / share | — | — | — | — | — | — | — | — |
Leadershipsynced from SEC 56d ago
- Meury William Chief Executive Officer · Director
- Upadhyay Suketu EVP & Chief Financial Officer
- Cagnoni Pablo J President, Global Head of R&D
- Stein Steven H CMO & Head of Late-Stage Dev.
- 667, L.p. Director
- Baker Bros. Advisors (gp) Llc Director
- Baker Bros. Advisors Lp Director
- Baker Brothers Life Sciences Lp Director
- Baker Felix Director
- Baker Julian Director
- Clancy Paul J Director
Officers and board are drawn from INCY’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- Jun 3 +6.2% one-day move
- Mar 30 Officer or director change reported in an 8-K
- Mar 26 Officer or director change reported in an 8-K
- Feb 10 −8.2% one-day move
- Feb 6 +5.5% one-day move
- Dec 31, 2025 FY2025 net income +3845% YoY
- Dec 19, 2025 +5.5% one-day move
- Dec 12, 2025 Officer or director change reported in an 8-K
- Dec 8, 2025 −5.7% one-day move
- Nov 3, 2025 +8.7% one-day move
- Oct 3, 2025 Officer or director change reported in an 8-K
- Aug 13, 2025 +5.2% one-day move
- Aug 7, 2025 Officer or director change reported in an 8-K
- Jul 29, 2025 +10.3% one-day move
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Recent SEC filingssynced from SEC 51d ago
- DEF 14A Proxy statement
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report